OBX (Obsidian Therapeutics) OCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBX Obsidian Therapeutics Inc OBX
8 GF Score
Price $27.50
View Full Analysis

What is Obsidian Therapeutics OCF Margin %?

Obsidian Therapeutics OBX -1.79% 8 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates OBX with a GF Score™ of 8/100.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Obsidian Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was $-90.39 Mil. Obsidian Therapeutics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Obsidian Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Obsidian Therapeutics's current OCF Yield % is -16,900.00%.

The historical rank and industry rank for Obsidian Therapeutics's OCF Margin % or its related term are showing as below:


OBX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -63.9
* Ranked among companies with meaningful OCF Margin % only.

Obsidian Therapeutics OCF Margin % Related Terms

Obsidian Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Obsidian Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Obsidian Therapeutics OCF Margin % Chart

Obsidian Therapeutics Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 0.00

Obsidian Therapeutics Semi-Annual Data
Dec24 Dec25
OCF Margin % 0.00 0.00
OBX
8GF Score
Obsidian Therapeutics Inc OBX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Obsidian Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Obsidian Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-90.393/0
= %

Obsidian Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-90.393/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Obsidian Therapeutics (OBX) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Obsidian Therapeutics and its competitors.
Is Obsidian Therapeutics' OCF Margin % too high?
Obsidian Therapeutics' current OCF Margin % is 0.00%. Overall, Obsidian Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' OCF Margin % compare to ?
Obsidian Therapeutics' OCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Obsidian Therapeutics and its competitors. Obsidian Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Obsidian Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Obsidian Therapeutics Business Description

Comparable Companies
Address 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
8GF Score

Get the complete analysis for OBX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.50
Price